Statement of Changes in Beneficial Ownership (4)
January 19 2021 - 1:51PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Mayne Pharma Ventures Pty Ltd |
2. Issuer Name and Ticker or Trading Symbol
Inhibitor Therapeutics, Inc.
[
INTI
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
1538 MAIN NORTH ROAD |
3. Date of Earliest Transaction
(MM/DD/YYYY)
1/15/2021 |
(Street)
SALISBURY SOUTH, SA, C3 5106
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_
X
_ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 1/15/2021 | | J(1) | | 2240488 | A | $0 | 204083227 | D (2) | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | On January 15, 2021, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") received a dividend of 2,240,488 shares of Common Stock paid by the Issuer on shares of Series B Convertible Preferred Stock held by Mayne Ventures, pursuant to the terms of such Series B Convertible Preferred Stock. |
(2) | These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd ("Mayne International") and Mayne Pharma Group Limited ("Mayne Group"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures may be deemed to be a director by deputization by virtue of its representation on the Board of Directors of the Issuer. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Mayne Pharma Ventures Pty Ltd 1538 MAIN NORTH ROAD SALISBURY SOUTH, SA, C3 5106 |
| X |
|
|
Mayne Pharma International Pty Ltd 1538 MAIN NORTH ROAD SALISBURY SOUTH, SA, C3 5106 |
| X |
|
|
Mayne Pharma Group Ltd 1538 MAIN NORTH ROAD SALISBURY SOUTH, SA, C3 5106 |
| X |
|
|
Signatures
|
Mayne Pharma Ventures Pty Ltd, By: /s/ Scott Richards, Director | | 1/18/2021 |
**Signature of Reporting Person | Date |
Mayne Pharma International Pty Ltd, By: /s/ Scott Richards, Director | | 1/18/2021 |
**Signature of Reporting Person | Date |
Mayne Pharma Group Limited: /s/ Scott Richards, Director | | 1/18/2021 |
**Signature of Reporting Person | Date |
Inhibitor Therapeutics (QB) (USOTC:INTI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitor Therapeutics (QB) (USOTC:INTI)
Historical Stock Chart
From Jul 2023 to Jul 2024